the use of arsenical therapy, such as arsenic trioxide, which is now established as a very effective treatment for acute promyelocytic leukemia [11, 12] .
Radiation therapy was undoubtedly the most effective form of antitumor treatment besides surgery for almost the first half of the twentieth century. Following Roentgen's discovery of x-rays, radiation therapy developed rapidly, although the methodology was primitive as compared to present day standards [13] . In the United States, Pusey and Senn reported results in treatment of lymphomas and leukemia in 1902 and 1903 [14, 15] . In some instances, the results were dramatic and suggested cures, although the development of relapse of disease and complications of treatment quickly altered the initial optimism.
Within a year of Roentgen's publication regarding the discovery of x-rays, another report of effective antitumor therapy appeared. Beatson, writing in the Lancet in 1896, noted benefit following oophorectomy in three patients with inoperable carcinoma of the breast [16] . The rationale for the use of oophorectomy was not because of any known hormonal effects recognized at that time. Hormonal mechanisms were, however, elucidated almost 50 years later when the role of androgens in prostate cancer was described by Huggins [17] .
Over the centuries, numerous nostrums were tried for systemic neoplastic disease. In 1767, Burrows (A New Practical Essay on Cancers, London) summarized, "that whatever has been proposed for the curing of cancers, are merely palliative medicines; and that no real specific has been hitherto discovered for that fatal disorder, although the physicians of all nations, from the time of Hippocrates to the present, have, by numberless researches and experiments, made trial of every thing in nature, from the most innocent drug, to the most virulent poison, both in the mineral and vegetable kingdoms; yet the disease still baffles the power of physic" [18] . Similar views are stated in 1914 when Bainbridge wrote, "Throughout the centuries, the sufferers of this disease have been the subject of almost every conceivable form of experimentation. The fields and forests, the apothecary shop and temple have been ransacked for some successful means of relief from the intractable malady. Hardly any animal had escaped making its contribution to hide or hair, tooth or toenail, thymus or thyroid, liver or spleen, in the vain search for a means of relief' [19] .
Late in the nineteenth century a surgeon, William Coley, developed a mixture of bacterial toxins known as Coley's toxin which induced regression of some tumors [20] . Other sera and bacterial toxins were developed, since one theory of the causation of cancer was the concept of some unidentified organism as a causative agent [21] .
Other therapeutic measures included blood transfusions, splenectomy, thyroidectomy, oxygen therapy, fever therapy, pituitary extract, and the use of organ extracts such as extracts of animal spleen, bone marrow, lymph nodes, pancreas, stomach, and small intestine [ 19] . Vitamins and minerals were also administered. Starvation diets were recommended by some physicians on the basis of the observation of cachexia in cancer patients, considered to be beneficial by depriving the tumor of nutritional needs [22] .
The lack of effective treatment did not deter claims for treatment benefits. Bryant, writing in the Boston Medical and Surgical Journal (1921), stated, "decided advances have been made in the past fifteen years and cancer may now be considered a somewhat preventable, somewhat curable disease" [23] . In 1920, however, in an editorial in the Canadian Practitioner and Review, the author commented on publicity arising from the use of an anti-cancer serum, "the newspapers are full of the most objectionable items published in wholesale style, such as "cancer patients are markedly better" and "all are improved." From the standpoint of the patients alone, this is unadvisable, if not absolutely cruel" [24] .
However, during the 1920s and 1930s an important advance that aided in the development of the modem era of cancer treatment was the development of animal systems that were to be predictive for antitumor drugs [25] [26] [27] . These systems laid the groundwork for subsequent drug screening programs.
The origins of effective chemotherapy for cancer date to World War I when mustard gas (sulfur mustard) was used. The blood and bone marrow findings in cases of mustard gas poisoning were described by Krumbhaar and later by Krumbhaar and Krumbhaar in 1919 [28, 29] . The time sequence of marrow depression revealed a maximal effect at two weeks after exposure when mortality was highest. Deaths were attributed in some cases to pneumonia associated with leucopenia. Autopsies revealed atrophy of lymphoid and testicular tissue as well as hypoplasia of the bone marrow.
In 1929, Berenblum, in studying carcinogenesis, observed that sulfur mustard was "anti-carcinogenic" [30] . In attempting to enhance the development of tumors induced by a carcinogenic tar, Berenblum and Riley-Smith added a solution of mustard gas, assuming that the local irritant effect of the mustard gas would induce hyperemia that was beneficial to tumor development. As described by the authors, the result was diametrically opposite. The mustard gas application inhibited the induction of tumors, and further experiments suggested that this was mediated by an effect of mustard gas on the animal rather than some interaction with the carcinogenic substance. Berenblum and Riley-Smith continued to investigate the "anticarcinogenic" effects of mustard gas, observing that inhibition of tumors induced by other carcinogens such as dibenzanthracene also occurred with mustard gas [31] . Other topical irritants were studied for tumor inhibition, and the only other agent not closely related to mustard gas with some tumor inhibitory activity was noted to be cantharidin.
Recognition of the possible importance of sulfur mustards in cancer research was later cited. Dr. James Ewing at the Memorial Hospital in New York recommended the study of the effects of mustard gas on experimental tumors, reported in 1931 [32] . Adair and Bagg applied a solution of mustard gas to the skin of normal mice and to a tumor induced by a chemical carcinogen [32] . Tumor regression was evident in the cutaneous tumor although autopsy showed a metastatic lung nodule in the animal. Varying doses of mustard gas application to the skin of the rabbit were assessed to determine appropriate doses for local use. This was followed by the application of topical mustard gas to cutaneous lesions of twelve patients and intratumoral injection in one individual at the Memorial Hospital in New York and reported by Adair [34] . It was suggested that the clinical application to neoplastic disease was possible. In fact, in 1942, Gilman, Goodman, Philips, and Allen at Yale discovered the antitumor activity of nitrogen mustard (methyl-bis) (beta-chlorethyl) (amine hydrochloride) [35] . The use of these compounds was restricted due to war time secrecy; hence the publication was delayed until 1946.
Interestingly, major textbooks of cancer medicine have erroneously attributed the initial use of nitrogen mustard to findings of exposure to mustard gas following an explosion that occurred in Bari Harbor in 1943 [36, 37] . The initial clinical trial occurred at Yale in May 1942 [35] .
The initial clinical trial of nitrogen mustard was reviewed by Gilman almost 20 years later [35] . He stressed that prior to clinical trial there were thorough animal studies conducted. Pharmacologic studies of the nitrogen mustard in rabbits revealed a remarkable sensitivity of lymphoid tissues to cytotoxic action of the nitrogen mustards.
It seemed natural, therefore, to examine the susceptibility of lymphoma to the nitrogen mustards. Gilman, Goodman, and Philips who had made the observations in rabbits turned to Thomas Dougherty, an anatomist, who first studied the compounds in mice, to ascertain the lethal dose and bone marrow effects. Doughtery, who was working with Gardner on a transplanted lymphoma, originally from an estrogen treated mouse, ultimately known as the Gardner lymphosarcoma, tried nitrogen mustard in a mouse with an advanced tumor. The tumor began to regress after two injections and became impalpable. The tumor recurred and was successfully treated although there was less regression than noted with the initial treatment. The animal, whose survival with this type of tumor was generally three weeks, survived for 84 days.
The observation was followed by testing in several other animal lymphomas and leukemias. None demonstrated the striking effect noted in the Gardner lymphosarcoma, and in some the treatment was completely ineffective. Gilman later wrote, "I have often thought that if we had by accident chosen one of these leukemias, in which there was absolutely no therapeutic effect, we might possibly have dropped the whole project" [34] . This serendipitous choice was paralleled in the human trial that followed.
In May 1942, a therapeutic trial in man was carried out under the supervision of Dr. Gustav E. Lindskog, an Assistant Professor of Surgery. The patient was described as "an x-ray resistant patient in the terminal stages of lymphosarcoma." The patient was a man, aged 48, who had received radiation therapy in March 1941 with considerable reduction in tumor involving the right tonsil, cervical nodes and axilla as well as mediastinum. In December 1941, he had recurrent disease treated by radiation therapy. In May 1942, he again received radiation therapy to treat the disease which now was associated with neck and facial edema, venous dilatation of the upper chest, and inability to adduct his arms due to large axillary masses. During this treatment, the patient did not respond to the radiation, so ten consecutive daily doses of nitrogen mustard 0.1 mg/kg were administered daily for 10 days.
On the fourth day of therapy, improvement was noted and by the last day of treatment, all signs and symptoms of his disease were gone. The response of the patient was striking and very much like the observations in the animal tumor.
The patient relapsed after one month, was then treated with a lesser dose (he experienced severe leuconeutropenia after the initial treatment) as well as thrombopenia (22,000 platelets/mm3) and some cutaneous purpura. He received a third course three weeks later to which he did not respond.
These observations generated considerable excitement and were followed by treatment of several patients who were in the terminal stages of malignant disease in a variety of tumors. Early reports documented some dramatic responses in Hodgkin's disease patients who had become refractory to radiation therapy. An example is the case of a 33-year-old woman who presented with dyspnea, cough, motor and sensory paresis of the right arm, and adenopathy of the axilla, neck and mediastinum. The patient also had edema of the breasts, and fevers to 103°F. Following four doses of nitrogen mustard at 0.1 mg/kg, improvement developed with disappearance of fever, dyspnea, and cough. The edema of her arms and breasts receded completely with 75 percent reduction in adenopathy.
As in the animal experiments, some tumors were resistant to the treatment. The clinical results in the acute leukemias were disappointing. No benefit was noted in melanoma, cervical carcinoma, and some lymphoma patients.
As expected from the animal data, bone marrow depression was a major toxic effect of the treatment. In the animal studies, the bone marrow suppression was reversible, and a fairly wide margin existed between marrow suppressive and lethal doses. As noted, the initial human dose was 0.1 mg/kg daily for 10 days. At three weeks following treatment, the total white count was 200 cu/mm and severe thrombopenia was noted. In man, the marrow recovery was prolonged in some instances, so dose modifications were utilized. [42] . The conclusion was that the nitrogen mustards were not a cure for neoplastic diseases and the tumor regressions were temporary. It was suggested that laboratory and clinical studies should continue in the hope that certain types of cancer might prove to be unusually sensitive to these agents and that compounds with more selective action on cancer tissue might be discovered.
During the period of the development of nitrogen mustards, the era of effective antibiotic therapy for infectious diseases began. By analogy, some investigators believed that one agent could be developed to cure turmors -the "magic bullet." This view was not shared by Gilman and colleagues who noted the variation in lymphomas and stated that it was unlikely that any compound would inhibit growth of all cancer cells [35] .
Following the introduction of nitrogen mustard into clinical practice, other types of alkylating agents were developed many of which are in clinical practice today, most notably chlorambucil, melphalan, busufan, and cyclophosphamide [43] .
Interestingly the clinical spectrum of their effectiveness is minimally changed from the initial report, although the toxicities differ.
The use of an antifolate compound was reported by Sidney Farber, initiating the development of antimetabolite therapy [44] . This was followed by the use of purine and pyrimidine analogs. Subsequently antitumor antibiotics, platinum compounds, imidizole compounds, vinca rosea alkaloids, taxols, camptothecin analogs, and biologic agents have become part of the therapeutic roster for neoplastic diseases [45] .
The search for an anticancer agent that is selective for tumor, sparing normal tissues, continues to the present day. The vast increase in knowledge of biologic, genetic and molecular aspects of neoplastic disease has led to more specific forms of therapy including targeted forms of treatment, such as the anti-CD20 antibody for lymphoid malignancies and most recently STI 571 which is a specific inhibitor of the BCL-ABL fusion gene characterizing chronic myelogenous leukemia [46, 47] . The long-term effects of the newer targeted treatments had not been defined, but they are more specific and less toxic than conventional cytotoxic agents whose discovery led to the modem era of cancer treatment.
